Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: Implications for HIV transmission

AIDS

Volumn 27, Issue 13, 2013, Pages 2141-2153

  Van De Wijgert, Janneke H H M ^a,b   Verwijs, Marijn C ^b,c   Turner, Abigail Norris ^d   Morrison, Charles S ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d OHIO STATE UNIVERSITY   (United States)

^e FHI 360   (United States)

Author keywords

Bacterial vaginosis; Combined oral contraception; Depot medroxyprogesterone acetate; HIV; Systematic review; Vaginal candidiasis; Vaginal microbiome; Vaginal microbiota

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ARTICLE; BACTERIUM CULTURE; COMBINED ORAL CONTRACEPTION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LACTOBACILLUS; MICROBIOME; NUGENT SCORING; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMATIC REVIEW; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINITIS; VIRUS TRANSMISSION;

CANDIDIASIS, VULVOVAGINAL; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HIV INFECTIONS; HUMANS; MEDROXYPROGESTERONE ACETATE; RISK ASSESSMENT; VAGINOSIS, BACTERIAL;

EID: 84884500073     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836290b6     Document Type: Article

References (59)

1. World Health Organization, Department of Reproductive Health and Research (2012). Hormonal contraception and HIV. Technical statement. http://www.who.int/reproductive health/publications/family-planning/rhr-12-8/en/ index.html. [Accessed 5 February 2013].
2. United Nations, Department of Economic and Social Affairs, Population Division (2011). World contraceptive use 2011. http://www.un.org/esa/population/ publications/contraceptive 2011/contraceptive2011.htm. [Accessed 5 February 2013].
3. Blish CA, Baeten JR. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011; 65:302-307.
4. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2012; 31:79-97.
5. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
6. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
7. Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS 2010; 24 (Suppl 4):S15-S26.
8. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert, et al. Intravaginal practices, bacterial vaginosis and HIV infection in women: individual person data meta-analysis. PloS Med 2011; 8:e1000416.
9. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-1911.
10. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50 (6 Suppl 1):S1-S195.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
12. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.
13. van de Wijgert JHHM, Morrison CS, Cornelisse PGA, Munjoma M, Moncada J, Awio P, et al. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 2008; 48:203-210.
14. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chonan B, Martin HL Jr, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
15. Pettifor A, Delany S, Kleinschmidt I, Miller WC, Atashili J, Rees H. Use of injectable progestin contraception and risk of STI among South African women. Contraception 2009; 80:555-560.
16. Gupta K, Hillier SL, Hooton TM, Roberts PL, Stamm WE. Effects of contraceptive method on vaginal microbial flora: a prospective evaluation. J Infect Dis 2000; 181:595-601.
17. Riggs M, Klebanoff M, Nansel T, Zhang J, Schwebke J, Andrews W. Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis 2007; 34:954-959.
18. Watts H, Springer G, Minkoff H, Hillier SL, Jacobson L, Moxley M, et al. The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women. J Acquir Immune Defic Syndr 2006; 43:161-168.
19. Holzman C, Leventhal JM, Qiu H, Jones NM, Wang J. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health 2001; 91:1664-1670.
20. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 37:864-869.
21. Lan PT, Lundborg CS, Phuc HD, Sihavong A, Unemo M, Chuc NT, et al. Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. Sex Transm Infect 2008; 84:126-132.
22. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK. Higher-risk behavioural practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 2005; 106:105-114.
23. Schwebke J, Desmond RA, Oh MK. Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis 2004; 31:433-436.
24. Egbe CA, Onwufor UC, Omoregie R, Enabulele OI. Female reproductive tract infections among vaginal contraceptive users in Benin City, Nigeria. Genomic Med Biomarkers Health Sci 2011; 3:49-52.
25. Schwebke JR, Desmond R. Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis 2005; 32:654-658.
26. Plitt SS, Garfein RS, Gaydos CA, Strathdee SA, Sherman SG, Taha T. Prevalence and correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis 2005; 32:446-453.
27. Cohen CR, Duerr A, Pruithithada N, Rugpao S, Hillier S, Garcia P, et al. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. AIDS 1995; 9:1093-1097.
28. McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, et al. A prospective study of risk factors for bacterial vaginosis in HIV-1 seronegative African women. Sex Transm Dis 2008; 35:617-623.
29. Ocak S, Cetin M, Hakverdi S, Dolapcioglu K, Gungoren A, Hakverdi AU. Effects of intrauterine device and oral contraceptives on vaginal flora and epithelium. Saudi Med J 2007; 28:727-731.
30. Eschenbach DA, Patton DL, Meier A, Thwin SS, Aura J, Stapleton A, et al. Effects of oral contraceptive use on vaginal flora and vaginal epithelium. Contraception 2000; 62:107-112.
31. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. DMPA-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 2000; 96:431-439.
32. Tibaldi C, Cappello N, Latino MA, Masuelli G, Marini S, Benedetto C. Vaginal and endocervical microorganisms in symptomatic and asymptomatic nonpregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15:670-679.
33. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004; 104:926-930.
34. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis 2007; 39:584-588.
35. Enweani IB, Gugnani HC, Okobia R, Ojo SB. Effects of contraceptives on the prevalence of vaginal colonization with Candida species in Edo State, Nigeria. Rev Iberoam Micol 2001; 18:171-173.
36. Grigoriou O, Baka S, Makraris E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006; 126:121-125.
37. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996; 7:182-187.
38. Hart G. Factors associated with trichomoniasis, candidiasis and bacterial vaginosis. Int J STD AIDS 1993; 4:21-25.
39. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009; 144:68-71.
40. Linhares LM, Witkin SS, Miranda SD, Fonseca AM, Pinotti JA, Ledger WJ. Differentiation between women with vulvovaginal symptoms who are positive or negative for Candida species by culture. Infect Dis Obstet Gynecol 2001; 9:221-225.
41. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187:569-574.
42. Guzel AB, Ilkit M, Akar T, Burgut R, Demir SC. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification vaginal yeast species. Med Mycol 2011; 49:16-25.
43. Barousse MM, van der Pol BJ, Fortenberry D, Orr D, Fidel PL Jr. Vaginal yeast colonization, prevalence of vaginitis, and associated local immunity in adolescents. Sex Transm Infect 2004; 80:48-53.
44. Blum M, Gilerovitch M, Benaim J, Appelbaum T. The correlation between Chlamydia antigen, antibody, vaginal colonization and contraceptive method in young unmarried women. Adv Contracept 1990; 6:41-45.
45. Ginter G, Soyer HP, Rieger E. Vaginal yeast colonization and promiscuity. A study of 197 prostitutes. Mycoses 1992; 35:177-180.
46. Hyman RW, Herndon CN, Jiang H. The dynamics of the vaginal microbiome during infertility therapy with in vitro fertilization-embryo transfer. J Assist Reprod Genet 2012; 29:105-115.
47. Jakobsson T, Forsum U. Changes in the predominant human lactobacillus flora during in vitro fertilization. Ann Clin Microbiol Antimicrob 2008; 7:14.
48. Gustafsson RJ, Ahrne S, Jeppsson B, Benoni C, Olsson C, Stjernquist M, et al. The Lactobacillus flora in vagina and rectum of fertile and postmenopausal healthy Swedish women. BMC Womens Health 2011; 11:17.
49. Gajer P, Brotman RM, Gyoyun B, Sakamoto J, Schü tte UME, Zhong X, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012; 4:132ra52.
50. Srinivisan S, Liu C, Mitchell CM, Fiedler TL, Thomas KK, Agnew KJ, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One 2010; 5:e10197.
51. Lopes dos Santos Santiago G, Tency I, Verstraelen H, Verhelst R, Trog M, Temmerman M, et al. Longitudinal qPCR study of the dynamics of L. crispatus, L. iners, A. vaginae, (sialidase-positive) G. vaginalis, and P. Bivia in the vagina. PLoS One 2012; 7:e45281.
52. Jespers V, Menten J, Smet H, Poradosú S, Abdellati S, Verhelst R, et al. Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests. BMC Microbiol 2012; 12:83.
53. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011; 108 (Suppl 1):4680-4687.
54. Eschenbach DA, Thwin SS, Patton DL, Hooton TM, Stapleton AE, Agnew K, et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis 2000; 30:901-907.
55. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesi PR, et al. Vulvovaginal candidiasis; epidemiologic, diagnostic and therapeutic consideration. Am J Obstet Gynecol 1998; 178:303-311.
56. Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, et al. Vaginal microbiome and epithelial gene array in postmenopausal women with moderate to severe dryness. PLoS One 2011; 6:e26602.
57. Mishell DR, Dharma KM, Thorneycroft IH, Nakamura RM. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 1972; 113:372-376.
58. Huijbregts RPH, Helton ES, Michel KG, Sabaj S, Richter HE, GoepfertPA, et al.Hormonal contraception andHIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 2013; 154:1282-1295.
59. McGrory E, Romano J, Young Holt B, Manning J, Hemmerling A. multipurpose prevention technologies for reproductive health. Executive Summary of the Product Prioritization Stakeholder Meeting; 26October 2012; Washington, DC. http://www. cami-health.org/documents/2012-SAWG-Report-Executive Report.pdf. [Accessed 14 February 2013]. Development